We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 309.00
Bid: 309.00
Ask: 312.00
Change: 9.00 (3.00%)
Spread: 3.00 (0.971%)
Open: 304.00
High: 316.00
Low: 304.00
Prev. Close: 300.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

Tue, 06th Jul 2021 20:38

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

-----------

Hipgnosis Songs Fund Ltd - Guernsey-registered music intellectual property rights investor - Placing sees "significant" demand, exceeds target amount of GBP150 million. Places 128.6 million shares at 121 pence each, raising GBP155.6 million. Will have 1.21 billion shares in issue when new shares are admitted. Founder Merck Mercuriadis says: "I am once again delighted with the support from both our existing and new shareholders with an oversubscribed raise of over USD215 million, GBP156 million. We will deploy this immediately into our pipeline of songs and I am incredibly appreciative of the incredible songwriters who have entrusted us with their iconic works."

-----------

On the Beach Group PLC - Manchester-based online retailer of beach holidays - Proposes placing, totalling 5.0% of existing issued share capital. "Given the extended disruption to international travel from the UK throughout 2021 and the ongoing trading environment across the sector, the board believes it is in the group's best interest to seek supplementary financing now," company explains. At March 31, company has cash balance of GBP30.0 million, which excludes GBP24.1 million of customer monies held in a ring-fenced trust account and GBP11.8 million owing from airlines for forward refunding flights, and has access to an undrawn revolving credit facility of GBP75 million. Company adds: "Whilst the actions taken by the Group around cash management and credit facility negotiations have allowed it to continue to operate throughout the sustained disruption caused by the pandemic, the prolonged delay in the recovery of the UK travel sector has meant that the group's cash position has reduced to a level not foreseen at the time of the placing in May 2020."

-----------

Triple Point Social Housing REIT PLC - London-based real estate investment trust - Completes acquisition of 10 supported housing properties and exchanged contracts on a further two properties, comprising 56 individual units in total, for an aggregate consideration of about GBP14 million. The properties are located in the the North West of England, Yorkshire and the South East. "The group has entered into new FRI leases in respect of each of the properties for a minimum period of 20 years. The leases are with specialist regulated housing providers, including Blue Square Residential, Chrysalis Supported Housing and Independent Housing," company says. Adds: "The rents received under the leases are subject to annual, upward-only rent reviews, increasing in line with the consumer price index."

-----------

Tirupati Graphite PLC - graphite and graphene producer in Madagascar and India - Signs memorandum of understanding with Hanwa Co Ltd to expand markets for its suite of flake and speciality graphite products in Asia. Chief Executive Shishir Poddar says: "Given the East Asian markets are primarily international trading houses driven, we are delighted to have signed an MoU with Hanwa, which will significantly progress our marketing efforts in this important region. The Far East hosts extensive industrial and speciality graphite markets, which imports almost all of its graphite primarily from China. However, lithium-ion battery and its anode manufacturers are increasingly looking at the green credentials of their supply chain as well as diversification away from Chinese sources, which is where we can step in."

-----------

Destiny Pharma PLC - Brighton, England-based biotechnology firm - Enters into cooperative research and development agreement with US Department of Veterans Affairs, to further research NTCD-M3 for the prevention of recurrence of Clostridioides difficile infections. "Destiny Pharma will collaborate on this research project with the Edward Hines VA Hospital in Hines, Illinois, utilising their CDI research expertise to complete new preclinical studies that could support the administration of NTCD-M3 to a broader CDI patient population and therefore strengthen the market opportunity. The research project is planned to complete in the fourth quarter of 2021," company says. Financial terms are not disclosed.

-----------

Creightons PLC - manufacturer of personal care, beauty and fragrance products - Annual results for year ended March 31 due on Wednesday now delayed. Says its auditors they will not now be able to complete their audit. "The company anticipates a short delay and will publish a revised date for the announcement and the investor presentation as soon as the amended timetable is confirmed," company adds.

-----------

Altus Strategies PLC - mining royalty company - Joint venture in southern Mali ups landholding at Tabakorole gold project. Company holds a 49% equity interest and 2.5% net smelter return royalty on the project. The venture's landholding increased by 56% to 292 square kilometres at Tabakorole. Chief Executive Steven Poulton says: "Tabakorole is shaping up to be a significant gold discovery not just in southern Mali, but in the west African context. This 100 square kilometre increase in the JV project area is strategically significant as the new licence area hosts a potential north-westerly extension of the 5 kilometre long 'Asgard trend', which is defined by strong, and often coincident, geochemical and geophysical anomalies." Also says partner, Marvel Gold is "aggressively advancing" the project.

-----------

Baltic Classifieds Group PLC - advertising websites operator in the Baltics region - Over-allotment option for initial public offering granted by major shareholder Antler EquityCo for 30.0 million shares at 165p each. Company intends to raise around EUR120 million in the initial public offering, with 230.0 million shares being placed. Proceeds from the raise will then be used to repay existing debt. The IPO will include an offering of both new shares and existing shares to be sold by major shareholder Antler Equity Co, a company owned by funds advised by Apax Partners LLP.

-----------

Cloudbreak Discovery PLC - natural resource project generator - Investee Imperial Helium Corp spuds IHC Steveville 1 at 102/03-01-020-12W4M, Imperial Helium's first well on its Steveville helium property, located in Southeastern Alberta, on schedule. Company owns 1.3% stake in Imperial Helium. "IHC Steveville 1 is the first of two appraisal wells Imperial Helium plans to drill on the Steveville structure. This first well targets the crest of the Steveville structure. With surface casing set, the rig will drill forward and set intermediate casing in the Stettler Formation, before continuing to a target depth of 2,047 metres. Upon reaching the target objective, a comprehensive suite of well logs will be acquired and evaluated, before completing the well and proceeding with production testing," company says.

-----------

Live Co Group PLC - Surrey-based live events provider - Signs new contract with Singapore Zoo for Bricklive Brickosaurs from November 5, 2021 to May 2, 2022. "This is the first time we are working with Singapore Zoo and the first time we are partnering with a zoo in Asia," company says. Chair David Ciclitira adds: "This expansion into the Asian Zoo sector is something we have been looking to achieve for some time. As countries start to open globally, we have secured events in 3 continents - USA, Europe and now Asia."

-----------

Hutchmed (China) Ltd - Hong-Kong-based pharmaceutical company - Starts Phase I study of HMPL‑295, its investigative oral inhibitor of ERK, which is a downstream component of the RAS-MAPK pathway signalling cascade. "HMPL-295 has the potential to address intrinsic or acquired resistance from upstream mechanisms such as RAS, RAF and MEK. This is our first of multiple candidates in discovery addressing the RAS-MAPK pathway. The first patient was dosed on July 2," company says. The RAS-MAPK pathway is dysregulated in human diseases, particularly cancer, in which mutations or nongenetic events hyperactivate the pathway in more than 50% of cancers.

-----------

Gunsynd PLC - London-based investment firm - Investee Charger Metals Ltd expected to begin trading on the Australian Securities Exchange this Friday. Charger Metals successfully raised AUD6 million in the IPO, based on this Charger will have 50.4 million shares in issue. Gunsynd will hold 3.6 million shares in Charger representing approximately 7.1% of the company's issued share capital.

-----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Read more
5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read more
2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read more
2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
28 Mar 2024 13:02

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read more
28 Mar 2024 11:08

Hutchmed lung cancer treatment accepted for review in China

(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.

Read more
28 Mar 2024 08:08

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

Read more
22 Mar 2024 10:09

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Read more
28 Feb 2024 17:31

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Feb 2024 15:14

UK earnings, trading statements calendar - next 7 days

Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.